

Contact:

Karen A. Donato, Ph.D.
Vice President, Sales and Marketing
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

MaxCyte Hosts LIVE Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery.

Gaithersburg, MD, November 12, 2008 – MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that it will be hosting a live discussion with industry experts on the challenges in developing cell-based screening assays for drug discovery. The discussion is open to the industry and will be held by webinar on Thursday, November 13th from 2:00-3:00EST.

One of the respected industry experts leading this live discussion is Dr John Reardon, formerly Senior Vice President of Discovery Research Biology at GSK and now Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions Inc (IOS) in North Carolina. Dr Reardon will review the complexities of cell transfection technologies and challenge the webinar participants to consider the possibilities of creating more relevant assays if it were possible to transfect any molecule into any cell at any scale, while maintaining biological integrity and the high quality standards. His discussion will offer compelling arguments as to how the MaxCyte® STX System can reduce bottlenecks and improve the productivity of drug discovery groups.

Dr James Brady, Director Technical Applications, will lead the webinar participants through a technical presentation of the MaxCyte® STX System. Dr. Brady will demonstrate how the MaxCyte STX technology enables the large scale transfection of primary cells, cell lines, and stem cells with multiple loading agents at the same time, resulting in more relevant screening systems.

According to MaxCyte CEO Doug Doerfler, “We are delighted to have the enthusiastic validation for our technology from a such a renowned industry expert as Dr Reardon. The MaxCyte STX is being viewed by the pharmaceutical industry as an enabling technology for cell modification for both research and larger scale cell-based applications in drug discovery. The MaxCyte STX can produce a large number of transfected cells in minutes compared to current time-consuming and inconsistent methods. More assays can be developed and performed in a shorter period of time, increasing the likelihood of finding a successful drug candidate.”

To register for the free webinar visit www.maxcyte.com and click on the registration link. MaxCyte scientists will be available after the webinar to answer any technical questions relative to the performance and operation of the MaxCyte STX Scalable Transfection System. A recording of the webinar will be available on the MaxCyte website after the event.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. The MaxCyte transfection technology was originally developed as an enabling technology for cell therapy and is currently being used in a number of clinical trials around the world. Drawing upon this expertise in cell loading for cell therapy,

MaxCyte introduced this transfection technology into drug discovery applications as the MaxCyte STX Scalable Transfection System. The MaxCyte STX allows for the rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.

For more information, www.maxcyte.com

###